Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China.

ABSTRACT:

Introduction

A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection. We conducted a phase 3 study to evaluate the efficacy and safety of alfosbuvir in combination with daclatasvir in Chinese patients with HCV infection.

Methods

All patients received 600 mg alfosbuvir tablets plus 60 mg daclatasvir tablets once daily for 12 weeks. The primary endpoint was sustained virological response 12 weeks after the end of treatment (SVR12). A follow-up visit was done at week 4 and 12, and those who achieved SVR12 were followed up at post-treatment week 24.

Results

Of the 32

SUBMITTER: Hua R 

PROVIDER: S-EPMC10651614 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature